OPT-80, a macrocyclic antimicrobial agent for the treatment of Clostridium difficile infections: a review.
BACKGROUND
Clostridium difficile-associated diarrhoea has become a major problem over the last years. Increasing incidence and more severe clinical cases initiated the search for new treatment options.


OBJECTIVE
OPT-80, also known as tiacumicin B, lipiarmycin or PAR-101, is a macrocyclic antimicrobial with little or no systemic absorption after oral administration and narrow activity spectrum against Gram-positive aerobic and anaerobic bacteria.


METHODS
Data on OPT-80 available from published studies, presentations at conferences and the manufacturer were collected and reviewed.


CONCLUSIONS
The in vitro studies of OPT-80 and clinical C. difficile strains showed high activity at low concentrations. Safety and efficacy of the drug were found to be favourable. More Phase II and III clinical trials are to be completed.
Gerber
Michael
M
University Hospital Leipzig, Institute for Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, Paul-List-Street 13-15, 04103 Leipzig, Germany.
Ackermann
Grit
G
D000818:Animals; D000890:Anti-Infective Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016360:Clostridioides difficile / Q000187:drug effects* / Q000254:growth & development; D004761:Enterocolitis, Pseudomembranous / Q000188:drug therapy* / Q000382:microbiology; D006027:Glycosides / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D008826:Microbial Sensitivity Tests; D015394:Molecular Structure; D016896:Treatment Outcome
D000890:Anti-Infective Agents; D006027:Glycosides; C487655:OPT 80